Vol.

No.

November 05, 2021Nov 05, 2021

Free

DOWNLOAD THE PDF

Caryn Lerman’s AACI presidential initiative: Close the diversity gap in the cancer centers’ workforce

Cover Story

Free Health Equity

Caryn Lerman’s AACI presidential initiative: Close the diversity gap in the cancer centers’ workforce

By Matthew Bin Han Ong

The Association of American Cancer Institutes is designing two programs to address systemic underrepresentation of racial and ethnic minority physicians and scientists in leadership positions in oncology.

Cancer History Project Free NCI

Sharpless: It’s time to confront the current reality of cancer and unravel it

By Alice Tracey

Free Obituary

Elihu H. Estey: Leukemia expert, statistician, gentle soul and friend

By Roland B. Walter, Andreas Hochhaus and Robert Peter Gale

Free Obituary

Edmund Gehan, creator of the “rule of 14” and the Wilcoxon-Gehan test, dies at 92

By Becky Slack Tidwell, J. Jack Lee, John Hanfelt and Donald A. Berry

Free In the Archives

From naïve beginnings: Oral histories and the future of NCI

Clinical Free Trials & Tribulations

No longer “experimental”—Prostate cancer patients should have access to proton therapy

By Shaakir Hasan

In Brief

Blanton Tolbert named Case Comprehensive Cancer Center’s first associate director for DEI

Case receives NCI merit extension

Fidel Valea appointed to leadership roles in gynecologic oncology at Northwell Health

SU2C establishes $3.25M head and neck cancer research team

Benjamin Young named program manager at the Marvin & Concetta Greenberg Pancreatic Cancer Institute

Baptist Health partners with ALA in ‘Saved By the Scan’ campaign

Mount Sinai Health System and BronxCare Health System open cancer facility

Clinical Roundup

Roswell Park researchers find β-AR stress pathway fuels tumor growth

University of Utah study finds risk of age-related diseases may be higher in younger B-NHL survivors

ALA survey identifies gaps in lung cancer awareness

Johns Hopkins Medicine study shows copper + disulfiram effective in childhood medulloblastoma

Drugs & Targets

Scemblix receives FDA approval for Ph+ CML

NCI Trials

NCI Trials for Nov. 2021

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.For further information, contact the principal investigator listed.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 05 - February 06, 2026